J Korean Ophthalmol Soc.  2014 Apr;55(4):493-497.

Clinical Efficacy of Polyhexamethylene Biguanide Lid Scrub on Demodex Blepharitis

• Moon JH
• Kim JC

Abstract

PURPOSE
To evaluate the treatment efficacy of polyhexamethylene biguanide (PHMB) lid scrub on Demodex blepharitis.
METHODS
Thirty-one patients diagnosed with Demodex blepharitis were evaluated every 2 weeks during 8 weeks of lid scrub treatment with 0.4% PHMB. Patients underwent epilation of 4 eyelashes in each eye, and the number of Demodex lesions was counted. The patients answered questionnaires regarding ocular surface discomfort and underwent ophthalmologic exams including slit lamp and tear breakup time (TBUT). Compliance was recorded as 1 of 3 stages (good, moderate, poor).
RESULTS
One patient was excluded for poor compliance. After PHMB lid scrub for 8 weeks, Demodex count was reduced in 28 of 30 patients (pre-PHMB 7.9 +/- 3.6 counts, post-PHMB 2.2 +/- 2.4 counts, p < 0.01). In addition, TBUT showed a statistically significant increase after PHMB lid scrub (pre-PHMB 2.7 +/- 0.8 seconds, post-PHMB 3.4 +/- 0.9 seconds, p < 0.01). Ocular surface disease index (OSDI) score was reduced in 28 of 30 patients (pre-PHMB 22.0 +/- 10.7 points, post-PHMB 7.4 +/- 6.0 points, p < 0.01).
CONCLUSIONS
Eight weeks of treatment with polyhexamethylene biguanide lid scrub on Demodex blepharitis had good treatment efficacy for reducing Demodex counts and OSDI scores and increasing TBUT.

Keyword

Demodex blepharitis; Polyhexamethylene biguanide

MeSH Terms

Blepharitis*
Compliance
Eyelashes
Hair Removal
Humans
Surveys and Questionnaires
Tears
Treatment Outcome

Figure

• 

  Figure 1. Photograph demonstrating ocular Demodex in Demodex blepharitis. Demodex Brevis, Demodex folliculum and eyelash observed by optical microscope (×100).

Reference

References

1. Basta-Juzbasić A, Subić JS, Ljubojević S. Demodex folliculorum in development of dermatitis rosaceiformis steroidica and rosa-cea-related diseases. Clin Dermatol. 2002; 20:135–40.

2. English FP, Nutting WB. Demodicosis of ophthalmic concern. Am J Ophthalmol. 1981; 91:362–72.

3. Coston TO. Demodex folliculorum blepharitis. Trans Am Ophthalmol Soc. 1967; 65:361–92.

4. Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinical importance of Demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004; 31:618–26.

5. Kamoun B, Fourati M, Feki J, et al. Blepharitis due to Demodex: myth or reality? J Fr Ophtalmol. 1999; 22:525–7.

6. Humiczewska M. Demodex folliculorum and Demodex brevis (Acarida) as the factors of chronic marginal blepharitis. Wiad Parazytol. 1991; 37:127–30.

7. Heacock CE. Clinical manifestations of demodicosis. J Am Optom Assoc. 1986; 57:914–9.

8. Lee SH, Chun YS, Kim JH, et al. The relationship between Demodex and ocular discomfort. Invest Ophthalmol Vis Sci. 2010; 51:2906–11.

9. Gao YY, Di Pascuale MA, Elizondo A, Tseng SC. Clinical treatment of ocular demodecosis by lid scrub with tea tree oil. Cornea. 2007; 26:136–43.

10. Larkin DF, Kilvington S, Dart JK. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology. 1992; 99:185–91.

11. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005; 46:3089–94.

12. Baima B, Sticherling M. Demodicidosis revisited. Acta Derm Venereol. 2002; 82:3–6.

13. Türk M, Oztürk I, Sener AG, et al. Comparison of incidence of Demodex folliculorum on the eyelash follicule in normal people and blepharitis patients. Turkiye Parazitol Derg. 2007; 31:296–7.

14. Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol. 1993; 128:650–9.

15. Kim JT, Lee SH, Chun YS, Kim JC. Tear cytokines and chemo-kines in patients with Demodex blepharitis. Cytokine. 2011; 53:94–9.

16. Gao YY, Di Pascuale MA, Li W, et al. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol. 2005; 89:1468–73.